Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Krüger H, Greiner W.

Eur J Health Econ. 2015 Jun;16(5):471-88. doi: 10.1007/s10198-014-0586-4.

2.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046.

PMID:
18462851
3.

The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.

Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Krüger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, Eichner M.

BMC Infect Dis. 2014 Jan 22;14:40. doi: 10.1186/1471-2334-14-40.

4.

Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.

Andersohn F, Bornemann R, Damm O, Frank M, Mittendorf T, Theidel U.

GMS Health Technol Assess. 2014 Oct 30;10:Doc03. doi: 10.3205/hta000119.

5.

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.

Value Health. 2007 Mar-Apr;10(2):98-116.

6.

Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.

Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.

BMC Infect Dis. 2015 Oct 27;15:465. doi: 10.1186/s12879-015-1193-4.

7.

[A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].

Vitale F, Barbieri M, Dirodi B, Vitali Rosati G, Franco E.

Ann Ig. 2013 Jan-Feb;25(1):43-56. doi: 10.7416/ai.2013.1905. Italian.

PMID:
23435779
8.

Cost-effectiveness of childhood rotavirus vaccination in Germany.

Aidelsburger P, Grabein K, Böhm K, Dietl M, Wasem J, Koch J, Ultsch B, Weidemann F, Wichmann O.

Vaccine. 2014 Apr 7;32(17):1964-74. doi: 10.1016/j.vaccine.2014.01.061.

PMID:
24561052
9.

Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Brydak L, Roiz J, Faivre P, Reygrobellet C.

Clin Drug Investig. 2012 Feb 1;32(2):73-85. doi: 10.2165/11594030-000000000-00000.

PMID:
22201294
10.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

11.

Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in children.

Heikkinen T, Block SL, Toback SL, Wu X, Ambrose CS.

Pediatr Infect Dis J. 2013 Jun;32(6):669-74. doi: 10.1097/INF.0b013e3182840fe7.

PMID:
23271441
12.

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.

Pediatrics. 2007 Sep;120(3):e553-64.

PMID:
17698577
13.

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Ryan J, Zoellner Y, Gradl B, Palache B, Medema J.

Vaccine. 2006 Nov 17;24(47-48):6812-22.

PMID:
17034909
14.

Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.

Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D.

Value Health. 2011 Sep-Oct;14(6):800-11. doi: 10.1016/j.jval.2011.03.005.

15.

Potential cost savings attributable to influenza vaccination of school-aged children.

White T, Lavoie S, Nettleman MD.

Pediatrics. 1999 Jun;103(6):e73.

PMID:
10353970
17.

Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years.

Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA.

Arch Pediatr Adolesc Med. 2011 Feb;165(2):112-8. doi: 10.1001/archpediatrics.2010.182.

PMID:
20921341
18.
19.

Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.

Navas E, Salleras L, Domínguez A, Ibáñez D, Prat A, Sentís J, Garrido P.

Vaccine. 2007 Apr 20;25(16):3233-9.

PMID:
17324489
20.

Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI.

PLoS One. 2011;6(7):e22308. doi: 10.1371/journal.pone.0022308.

Items per page

Supplemental Content

Support Center